Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST

The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.

Related Keywords

Memorial Sloan Kettering Cancer Center ,New York ,United States , ,Bezuclastinib And Sunitinib ,Patients With Gastrointestinal Stromal Tumor ,Peak Trial ,Nct05208047 ,Williamd Tap ,D ,